FDA Approves First Oral PCSK9 Inhibitor - Top-Institutions - MDSpire

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 2 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Cardiology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Cardiology

Original Source(s)

FDA Approves First Oral PCSK9 Inhibitor

  • by Kathryn Wighton

  • July 16, 2026

Related Content

Association between the fibrosis-4 index and carotid atherosclerosis in Chinese patients with type 2 diabetes mellitus: a cross-sectional study

Diagnostic value of cardiovascular biomarkers for cerebral–cardiac syndrome risk in acute ischemic stroke

Prolonged Sleep Restriction May Increase Body Weight

In a pooled analysis of two randomized crossover trials, reducing nightly sleep by about 1.5 hours for 6 weeks was associated with modest increases in body weight and waist circumference without measurable changes in body composition.